A research-use or not-for-human-consumption label is not an FDA approval. FDA has warned about unapproved GLP-1 products sold with research-purpose labeling, and about quality, dosing, labeling, salt-form, storage, and counterfeit risks in unapproved or compounded GLP-1 products.

Two vials labeled "semaglutide" can come from very different supply chains with very different verification standards.

The FDA has published specific concerns about unapproved GLP-1 products: dosing errors, fraudulent products, mismatches in the form of the molecule (the salt form, where different chemical pairings of the active ingredient with a stabilizer affect both the dose math and the stability), labeling problems, and quality-control gaps.

The molecule's name on the vial doesn't carry information about any of those.